R. Edwards

Cancer Discovery · with Aguilar · 2018–2021

A researcher in the Science corpus: 2 papers; trusts 0 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Whom R. Edwards trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. Andrew Janowczyk

Papers from R. Edwards's perspective

Ordered by how strongly the researchers R. Edwards trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing (Nature Biotechnology)
  2. Who is afraid of black box algorithms? On the epistemological and ethical basis of trust in medical AI (Journal of Medical Ethics)
  3. Innate and adaptive immune cells in the tumor microenvironment (Nature Immunology)
  4. First-Line Nivolumab in Stage IV or Recurrent Non-Small Cell Lung Cancer
  5. Co-occurring genomic alterations define major subsets of KRAS - mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities (Cancer Discovery)
  6. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden (Genome Medicine)
  7. Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted… (Journal of Clinical Oncology)
  8. HistoQC: An Open-Source Quality Control Tool for Digital Pathology Slides (JCO Clinical Cancer Informatics)
  9. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity (Nature)
  10. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate… (Journal of Clinical Oncology)

Their papers